【产品介绍】：

生物活性：Telmisartan-d7 (BIBR 277-d7) is a deuterium labeled Telmisartan (HY-13955). Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
体外研究(In Vitro)：氢、碳和其他元素的稳定重同位素已被纳入药物分子中，主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注，因为它可能影响药物的药代动力学和代谢谱[1]。
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Telmisartan-d7 相关抗体:
Natriuretic Peptides A Antibody (YA1381)
Angiotensinogen Antibody (YA2097)
Natriuretic Peptides B Antibody (YA999)
Natriuretic Peptides B Antibody (YA1000)
Natriuretic Peptides B Antibody (YA1001)
AGTR2 Antibody (YA3090)
Angiotensin II Type 1 Receptor Antibody (YA3358)
分子量：521.66
Formula：C33H23D7N4O2
CAS 号：1794754-60-1
非标记 CAS：144701-48-4
中文名称：替米沙坦 d4-d7
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (544 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246.
 [Content Brief]
[2]. Maillard MP, et al. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther. 2002 Sep;302(3):1089-95.
 [Content Brief]
[3]. Xuan H, et al. Inhibition or deletion of angiotensin II type 1 receptor suppresses elastase-induced experimental abdominal aortic aneurysms. J Vasc Surg. 2017 Apr 20. pii: S0741-5214(17)30100-3.
 [Content Brief]
[4]. Torika N, et al. Intranasal telmisartan ameliorates brain pathology in five familial Alzheimer's disease mice. Brain Behav Immun. 2017 Apr 3.
 [Content Brief]
[5]. Aswar U, et al. Telmisartan attenuates diabetes induced depression in rats. Pharmacol Rep. 2017 Apr;69(2):358-364.
 [Content Brief]
[6]. Fujihara S, et al. The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo. Oncotarget. 2017 Jan 31;8(5):8536-8549.
 [Content Brief]